NASDAQ:ABUS - Arbutus Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.54 +0.13 (+2.95 %)
(As of 12/18/2018 10:19 AM ET)
Previous Close$4.41
Today's Range$4.41 - $4.54
52-Week Range$4.01 - $12.60
Volume617 shs
Average Volume165,653 shs
Market Capitalization$242.99 million
P/E Ratio-2.46
Dividend YieldN/A
Beta1.65
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
Previous Symbol
CUSIPN/A
Phone604-419-3200

Debt

Debt-to-Equity Ratio0.01
Current Ratio11.38
Quick Ratio11.38

Price-To-Earnings

Trailing P/E Ratio-2.46
Forward P/E Ratio-3.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.70 million
Price / Sales23.54
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.41 per share
Price / Book1.88

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-84,410,000.00
Net Margins-1,116.69%
Return on Equity-91.36%
Return on Assets-40.43%

Miscellaneous

Employees130
Outstanding Shares55,480,000
Market Cap$242.99 million
OptionableOptionable

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) issued its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.13. The biopharmaceutical company had revenue of $1.59 million for the quarter, compared to analysts' expectations of $0.23 million. Arbutus Biopharma had a negative return on equity of 91.36% and a negative net margin of 1,116.69%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

4 equities research analysts have issued 12-month target prices for Arbutus Biopharma's stock. Their predictions range from $5.00 to $9.00. On average, they expect Arbutus Biopharma's share price to reach $6.8333 in the next year. This suggests a possible upside of 50.5% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.

What is the consensus analysts' recommendation for Arbutus Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arbutus Biopharma.

What are Wall Street analysts saying about Arbutus Biopharma stock?

Here are some recent quotes from research analysts about Arbutus Biopharma stock:
  • 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (12/4/2018)
  • 2. Chardan Capital analysts commented, "We maintain our BUY rating and are increasing our 12-month price target to $11.00: We continue to believe that Arbutus has the potential to become a significant competitor in the chronic hepatitis B virus (HBV) infection treatment market. We believe that future progress updates from its pipeline programs could serve as potential value creation events for the stock over the next 12-18 months. First up will be interim data in 2 study of the Company’s lead RNAi asset, ARB-1467, used as combination therapy for HBV. The Company’s second generation capsid assembly inhibitor, ARB-506, is now being evaluated in a Phase 1 study, which dosed its first patient yesterday, in an initial cohort of healthy human volunteers, and could report topline data by mid-2019." (7/16/2018)

Has Arbutus Biopharma been receiving favorable news coverage?

Media coverage about ABUS stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arbutus Biopharma earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.

Who are some of Arbutus Biopharma's key competitors?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 69)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 60)
  • Dr. Elizabeth Howard, Exec. VP & Gen. Counsel (Age 64)
  • Mr. Bruce G. Cousins, Consultant (Age 57)
  • Mr. David C. Hastings, Chief Financial Officer (Age 57)

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (7.34%), Foresite Capital Management IV LLC (4.82%), BlackRock Inc. (4.37%), EcoR1 Capital LLC (2.22%), Morgan Stanley (1.85%) and Bank of Montreal Can (1.64%). View Institutional Ownership Trends for Arbutus Biopharma.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, PNC Financial Services Group Inc., Bank of Montreal Can and Algert Global LLC. View Insider Buying and Selling for Arbutus Biopharma.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, EAM Investors LLC, Morgan Stanley, Jennison Associates LLC, Vanguard Group Inc, Vanguard Group Inc., Sio Capital Management LLC and EAM Global Investors LLC. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $4.54.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $242.99 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is http://www.tekmirapharm.com.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  559
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel